Neil Bhowmick, PhD, examines the role of tissue fibroblastic cells in cancer initiation and progression. He studies the role of the tumor microenvironment in prostate cancer progression and mediators of metastatic progression through the use of in vivo model systems. Dr. Bhowmick is currently working on candidate therapeutics to address host-tumor interactions and the development of a biomarker platform to help distinguish indolent and aggressive cancer.

• Undergraduate: University of Florida, 1991
• Doctorate: University of Georgia, 1998

• Cancer Institute (Samuel Oschin Comprehensive Cancer Institute)
• Urologic Oncology
• Biomedical Sciences
• Cancer
• Medicine

• Society for Basic Urologic Research Young Investigator Award, 2009
• Ortho-McNeil Young Investigator Award, 2002
• Aventis Pharmaceuticals Leadership Development in Cancer Research Award, 2002
• AACR-AFLAC Scholar-in-Training Award, 2002
• Franklin Distinguished Doctoral Award, 1997

Click here for a list of peer-reviewed publications.

• Kiskowski MA, Jackson RS 2nd, Banerjee J, Li X, Kang M, Iturregui JM, Franco OE, Hayward SW, Bhowmick NA. Role for stromal heterogeneity in prostate tumorigenesis. Cancer Res. 2011;71(10):3459-3470.
• Haldar S, Dru C, Mishra R, Tripathi M, Angara B, Duong F, Fernandez A, Arditi M, Bhowmick NA. Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis. Scientific Reports. 2016;6:39257
• Mishra R, Haldar S, Placencio-Hickok V, Madhav A, Rohena-Rivera K, Agarwal P, Duong F, Angara B, Tripathi M, Liu Z, Gottlieb RA, Posadas EM, Wagner S, Bhowmick NA. Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. J Clin Invest. 2018;128:4472-4484.